Anaphylactic Reaction clinical trials

Explore recruiting anaphylactic reaction clinical trials.

Recruiting anaphylactic reaction studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Anaphylactic Reaction trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CA209-8KX Phase I/II pharmacokinetic multi-tumor study of subcutaneous formulation of nivolumab monotherapy

Spain, Netherlands, Italy, Poland, France

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Efficacy of Higher vs. Lower Doses of Dexamethasone in Patients With Acute Hypoxemic Respiratory Failure (Including ARDS) Caused by Infections (Including COVID-19)

Spain

Therapeutic use (Phase IV) EU CTIS Study details

PROPHY-SEIN - Evaluation of the effect of antibiotic prophylaxis during lumpectomy for breast cancer: prospective randomised double-blind noninferiority study of placebo vs cefazolin

France

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Phase 1/2a Dose Escalation and Cohort Expansion Study of the Safety, Tolerability, and Efficacy of Anti-LAG-3 Monoclonal Antibody (BMS-986016) Administered Alone and in Combination with Anti-PD-1 Monoclonal Antibody (Nivolumab, BMS-936558) in Advanced Solid Tumors

Finland, Norway, Denmark, France, Italy, Austria +3 more

Phase I and Phase II (Integrated)- Other EU CTIS Study details

Teicoplanin as Infection Prophylaxis in Pediatric Acute Myeloid Leukemia (Pro-Teico study) An open-label, randomized clinical trial on teicoplanin infection prophylaxis in pediatric patients with acute myeloid leukemia

Netherlands, Belgium, Spain, Denmark

Therapeutic confirmatory (Phase III) EU CTIS Study details

The effect of early Landiolol in patients with ST-elevation acute coronary syndrome undergoing primary percutaneous coronary intervention – A prospective, randomized, double- blinded, placebo controlled, phase IV pilot trial (STEMILAND-1)

Austria

Therapeutic use (Phase IV) EU CTIS Study details

Anaphylactic Reaction trials by city

Anaphylactic Reaction in Toronto Anaphylactic Reaction in Vancouver Anaphylactic Reaction in Montreal Anaphylactic Reaction in Calgary Anaphylactic Reaction in Edmonton Anaphylactic Reaction in Ottawa Anaphylactic Reaction in Winnipeg Anaphylactic Reaction in Quebec City Anaphylactic Reaction in Hamilton Anaphylactic Reaction in Kitchener Anaphylactic Reaction in London Anaphylactic Reaction in Halifax Anaphylactic Reaction in New York Anaphylactic Reaction in Los Angeles Anaphylactic Reaction in Chicago Anaphylactic Reaction in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease